Gemzar Gets Treatment IND for Advanced Pancreatic Cancer
INDIANAPOLIS--Eli Lilly and Company has received FDA approval to provide gemcitabine (Gemzar) to advanced pancreatic cancer patients through a Treatment Investigational New Drug program.
INDIANAPOLIS--Eli Lilly and Company has received FDA approvalto provide gemcitabine (Gemzar) to advanced pancreatic cancerpatients through a Treatment Investigational New Drug program.
The agent will be provided free of charge to patients who arenot candidates for surgery and who meet certain medical eligibilitycriteria. Patients may have been previously untreated or havehad one prior chemotherapy regimen. Physicians may call 1-800-621-7111for more information about the Treatment IND.
Articles in this issue
First Results of Avicidin Trials
Chemo Patients Often Develop Menstrual Irregularities
Growth Factor Receptor Blockade Moving From Laboratory to Clinic
Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigation
Vinorelbine Plus Chemo Promising in Advanced Disease
Bone Substudy a Part of Tamoxifen Prevention Trial
Ultrasound Breast Screens Useful in Selected Women
New Roles Forecast for Endocrine Therapy
Antisense Drug Against BCL-2 Effective in Animal Cancer Models
Anticancer Drugs From Zeneca in Regulatory Phase of Development
Osteosarcoma Chemo Regimens Debated
Primary Chemotherapy Allows Breast-Conserving Surgery in French Study
Cancer Care, Inc. Sponsors Make-Up Clinics for Chemo Patients
$2 Billion Budget for NCI Proposed
Risk of Gyn Cancer Increases After Diagnosis of Breast Cancer
Related Videos
Related Content
